Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex, Inc. (NASDAQ: GNPX) announced a virtual presentation led by President and CEO Rodney Varner at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. Varner will showcase the company's innovative gene therapies for cancer and diabetes, available on-demand from May 24. Genprex focuses on life-changing therapies, featuring its ONCOPREX® Nanoparticle Delivery System for cancer treatment and its lead candidate, REQORSA™, aimed at non-small cell lung cancer (NSCLC). The FDA has granted Fast Track Designation for REQORSA in combination therapies with Tagrisso® and Keytruda®.
Genprex, Inc. (NASDAQ: GNPX) announced that its Chief Medical Officer, Mark Berger, M.D., will participate in the 33rd Annual Cancer Progress Conference on May 12, 2022. The virtual panel discussion, titled "Into the Unknown – Bringing New Modalities into Solid Tumors," will focus on the positioning of cell-based and emerging immunotherapy platforms in solid tumors. Genprex is a clinical-stage gene therapy company aiming to create innovative therapies for cancer and diabetes, utilizing its ONCOPREX® Nanoparticle Delivery System for its lead product candidate, REQORSA™, targeting non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) has made significant advancements in its clinical programs in 2022. The company commenced patient treatment in the Phase 1/2 Acclaim-2 trial for non-small cell lung cancer (NSCLC) and received a second Fast Track Designation for its product REQORSA™ Immunogene Therapy. Additionally, Genprex has expanded its pipeline to include small cell lung cancer. CEO Rodney Varner expressed optimism about the company’s future as it pursues innovative gene therapy solutions for patients with serious health conditions.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in key conferences focused on its innovative therapies for cancer and diabetes. The presentations will be held during NobleCon 18 from April 19-21, 2022, with a specific session on April 20 at 11:30 a.m. ET. Additionally, Genprex will feature in the Alliance for Regenerative Medicine's virtual meeting from April 20-22, 2022. These events are crucial for showcasing Genprex's proprietary ONCOPREX® Nanoparticle Delivery System and the lead candidate, REQORSA™, targeting non-small cell lung cancer.
Genprex, Inc. (GNPX) announced the opening of patient enrollment for its Acclaim-2 clinical trial, evaluating the combination of REQORSA™ Immunogene Therapy and Keytruda® in late-stage non-small cell lung cancer (NSCLC) patients. This follows Genprex's prior FDA Fast Track Designation for similar treatments. The trial aims to establish the maximum tolerated dose and assesses the synergistic effects of the combination on progression-free survival. An interim analysis is planned after 50 events, with expectations to complete the Phase 1 portion by Q1 2023.
Genprex, a clinical-stage gene therapy company, will present at the BIO Europe Spring Investor Conference from March 28-31, 2022. President and CEO Rodney Varner will discuss the company's innovative gene therapies targeting cancer and diabetes. Genprex's lead product, REQORSA (quaratusugene ozeplasmid), aims to treat non-small cell lung cancer by utilizing the ONCOPREX Nanoparticle Delivery System, which is the first systemic gene therapy for cancer in humans. The presentation will be available on-demand, and Varner will also engage in virtual one-on-one meetings with participants.
Genprex, Inc. (NASDAQ: GNPX) announced the dosing of the first patient in its Acclaim-1 clinical trial, evaluating its lead drug, REQORSA, in combination with Tagrisso for late-stage non-small cell lung cancer (NSCLC) patients. This Phase 1/2 trial aims to improve responses in patients whose disease progressed after Tagrisso treatment. The FDA previously granted Fast Track Designation to REQORSA for this patient population. Positive preclinical data indicate that REQORSA may overcome resistance to Tagrisso.
Genprex, Inc. (NASDAQ: GNPX) announced that President and CEO Rodney Varner will discuss the Company's innovative gene therapies for cancer and diabetes at the upcoming BIO CEO and Investor Conference and Diamond Equity Research Conference. The BIO conference is scheduled for February 14-17, 2022, with on-demand presentations available starting February 11. The Diamond conference will take place on February 24, 2022, at 3 p.m. EST. These events will allow for virtual one-on-one meetings and follow-up questions. For more information, visit www.genprex.com.
Genprex, Inc. (NASDAQ: GNPX) announced promising preclinical findings in a study published in Cancers, demonstrating that its ONCOPREX® Nanoparticle Delivery System effectively restores FAS expression in mouse models of metastatic colorectal cancer. This delivery system showed potential in suppressing tumor growth and increasing survival rates. The company plans to expand its oncology programs, leveraging these results to explore additional therapeutic genes for various cancers. The ONCOPREX system is also pivotal in Genprex's ongoing lung cancer trials.
Genprex, Inc. has announced plans to accelerate the opening of clinical trial sites for the Acclaim-1 trial, which investigates the combination of REQORSA™ and AstraZeneca's Tagrisso® in treating non-small cell lung cancer (NSCLC). Four sites are opening to enroll patients in the Phase 1 portion of the trial, with additional sites anticipated for Phase 2. The trial will evaluate the therapy’s efficacy in patients previously treated with Tagrisso. An interim analysis will be conducted at 25 events, and the Phase 2 primary endpoint is progression-free survival.